Rates of relapses and serious adverse events in patients with GPA or MPA receiving rituximab for maintenance therapy: a multicentre, retrospective study

Gialouri C., Chalkia A., Koutsianas C., Chavatza K., Argyriou E., Panagiotopoulos A., Karamanakos A., Dimouli A., Orfanos P., Lagiou P., Thomas K., Tsalapaki C., Katsikas G., Boki K., Boumpas D., Petras D., Vassilopoulos D..

21^st International Vasculitis workshop, 7-10 April 2024, Barcelona